[Fabry disease: new clinical research--current therapeutic perspectives].
Beck
Michael
M
D000293:Adolescent; D000328:Adult; D002648:Child; D041321:Chromosomes, Human, X; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D017277:Drug Approval; D000795:Fabry Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005808:Genes, Recessive / Q000235:genetics; D006580:Genetic Carrier Screening; D006801:Humans; D007527:Isoenzymes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010641:Phenotype; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012729:Sex Chromosome Aberrations; D000519:alpha-Galactosidase / Q000009:adverse effects / Q000627:therapeutic use*
D007527:Isoenzymes; D011994:Recombinant Proteins; D000519:alpha-Galactosidase; C459420:agalsidase beta